Loading…
← CockpitCompetitor Analysis › 603222.SS Chimin Health Management Co., Ltd. Class AOpen in the cockpit ↗

Chimin Health Management Co., Ltd. Class A603222.SSCompetitor analysis, valuation and peers

China · CNY·Health Care›Pharmaceuticals: Major
Momentum weak 29
Mkt cap
$533M
US dollars, full cap
Free float
96%
of shares outstanding
$/day
$12.2M
20-day average traded
Fwd P/E
n/m
no positive forecast
ROIC−WACC
-13.4 pp
WACC 9.5%
Hurdle
n/a
no reverse DCF
Next earnings
162 days
29 Apr 2027
Close · CNYCN¥6.90
1D+0.1%
1W-3.9%
1M-13.6%
3M-23.6%
6M-30.9%
YTD-24.4%
1Y-31.1%
ATR %4.8%
52w lowhigh44.2% off high

What Chimin Health Management does

Employees: 1,890

Chimin Health Management at a glance

Size Chimin Health Management (603222.SS) is a China Health Care company (Pharmaceuticals: Major) with a market value of $533M, the 3541st largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥6.90 on 18 Nov 2026.

Performance Over six months the shares fell 30.9%, against -14.6% for the median peer and -20.0% for the China market (cap-weighted) — lowest of 19 in its peer set.

Growth Revenue grew 0.7% over the last twelve months (peer median +8.4%); the operating margin is -28.2% (peer median 11.0%).

Valuation It trades at 6.6× enterprise value to sales against a peer median of 5.2× (7th most expensive of 19).

Capital Return on invested capital runs 13.4 points below its cost of capital (9.5% WACC).

Next results Next results expected around 29 Apr 2027 (exchange calendar; dates can move).

Relative performance

8010021 May 202621 Aug 202618 Nov 2026Peer median 85603222.SS 69
Six months, rebased to 100: Chimin Health Management against the median of its 20 peers (local-currency closes).

Chimin Health Management financials

Reported figures in CNY; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
RevenueCN¥639MCN¥684MCN¥764MCN¥891MCN¥833M
Revenue growth—-10%-14%+7%—
Gross profitCN¥244MCN¥181MCN¥245MCN¥345MCN¥360M
EBITDAn/a-CN¥32.8MCN¥70.3MCN¥152MCN¥172M
Net income-CN¥251M-CN¥246M-CN¥59.7M-CN¥65.5MCN¥34.5M
Free cash flow-CN¥3.20M-CN¥56.6M-CN¥47.3M-CN¥4.97MCN¥19.2M
Capital expenditureCN¥44.6MCN¥46.2MCN¥122MCN¥149MCN¥196M
Total debtCN¥807MCN¥728MCN¥555MCN¥509MCN¥626M

Quarterly statements and history in the cockpit →

Chimin Health Management competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

0%+50%+100%+150%-20%0%+20%000919SUPRIYASENORESMOREPENLAB3004850026884559ZVRA003850EGTXINDPGUJTHEM688356603222.SS6-month return →1-month return →
Up and to the right = strong over both horizons. Chimin Health Management is the large dot.

Fundamentals: revenue growth against valuation

-50%0%+50%0×25×50×75×000919SUPRIYAEVONILESENORESMOREPENLAB3004850026884559ZVRA603676ACRSEGTXGUJTHEM688356603207603222.SSRevenue growth (TTM) →EV / Sales →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Chimin Health Management is the large dot.

Chimin Health Management competitors and peer comparison

How Chimin Health Management compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Chimin Health Management against its 20 peers (data as of 18 Nov 2026)
Measure603222.SSPeer medianRank in peer set
1-month return-13.6%-7.0%4th lowest of 20
6-month return-30.9%-14.6%lowest of 19
Distance from 52-week high-44.2%-38.7%6th lowest of 20
Revenue growth (TTM)+0.7%+8.4%8th lowest of 19
Operating margin-28.2%11.0%4th lowest of 19
EV / Sales6.6×5.2×7th most expensive of 19
ROIC minus cost of capital-13.4 pp-1.5 pp3rd lowest of 18

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginEV / SalesReq gDelivered g
Chimin Health Management 603222.SSChina$533M-31%+1%-28%6.6×n/an/a
Electra Therapeutics ETRAUnited States$530Mn/an/an/an/an/an/a
Jinling Pharmaceutical 000919.SZChina$529M-15%-8%1%0.7×2.4%+5.0%
Supriya Lifescience SUPRIYA.NSIndia$529M-15%+23%26%5.5×28.2%+15.8%
Evonile Pharma EVONILE.NSIndia$529Mn/a-5%12%16.2×49.3%-1.5%
Senores Pharmaceuticals SENORES.NSIndia$538M+3%+40%24%7.4×n/an/a
Morepen Laboratories MOREPENLAB.NSIndia$542M+121%+30%11%2.2×n/an/a
Beijing Science Sun Pharmaceutical 300485.SZChina$517M-29%-11%-8%5.6×n/an/a
Jinhe Biotechnology 002688.SZChina$550M-19%+7%5%1.8×1.0%+9.7%
Zeria Pharmaceutical 4559.TJapan$552M-12%+12%15%1.0×-12.3%+11.1%
Zevra Therapeutics ZVRAUnited States$552M-9%+75%31%2.4×-4.9%+51.6%
Xizang Weixinkang Pharmaceutical 603676.SSChina$513M-22%-8%16%2.3×-6.1%+9.6%
Boryung 003850.KSSouth Korea$554M-13%+6%6%0.9×-3.1%+12.6%
Aclaris Therapeutics ACRSUnited States$555M-23%-59%-1,412%69.1×n/an/a
Tianjin Lisheng Pharmaceutical 002393.SZChina$557M-24%-3%7%1.2×-5.8%+4.1%
Egetis Therapeutics EGTX.STSweden$509M+76%+27%-645%71.0×n/an/a
Zhong Zhu Healthcare 600568.SSChina$562M-22%-6%-34%6.2×n/an/a
Indaptus Therapeutics INDPUnited States$505M+147%n/an/an/an/an/a
Gujarat Themis Biosyn GUJTHEM.NSIndia$505M+2%+18%39%27.2×n/an/a
Jenkem Technology 688356.SSChina$563M-30%+52%11%8.7×36.4%+11.2%
Shanghai Xiao Fang Pharmaceutical 603207.SSChina$503M-17%+10%39%4.8×-5.4%+7.6%

Questions

Which companies are Chimin Health Management's closest peers?
The cockpit's peer set: Electra Therapeutics (ETRA), Jinling Pharmaceutical (000919.SZ), Supriya Lifescience (SUPRIYA.NS), Evonile Pharma (EVONILE.NS), Senores Pharmaceuticals (SENORES.NS), Morepen Laboratories (MOREPENLAB.NS), Beijing Science Sun Pharmaceutical (300485.SZ), Jinhe Biotechnology (002688.SZ).
Is Chimin Health Management expensive compared with its peers?
On ev / sales it trades at 6.6× against a peer median of 5.2×, 7th most expensive of 19 in its peer set.
How has Chimin Health Management stock performed?
Over six months to 18 Nov 2026 the shares returned -30.9% against -14.6% for the median peer; over one year -31.1%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.